VGT Stock Recent News
VGT LATEST HEADLINES
The markets came out of the gate higher across the board but those gains have evaporated.
Tech stocks are joining in on today's market gains on positive trade developments between the U.S.
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that an abstract on abenacianine for injection (VGT-309) will be featured at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. The poster will highlight data from the Phase 2B, multicenter VISUALIZE study (NCT06145048) evaluating the safety and efficacy of abenacianine in patients undergoing surgery.
The markets remain under pressure, including technology stocks, as the Fed meets to discuss interest rates.
Tech stocks remain under pressure, including a 2% decline in Apple stock, while the Dow Jones Industrial Average is eking out a slight gain.
It's a chaotic time in the market, that's for sure. The roller-coaster ride of 2025 has left many investors feeling confused and not a little bit fearful.
The markets are on pace to finish the week on a positive note after all is said and done.
Citi analyst Christopher Danely remains bullish on AI spending, publishing a report indicating that the impact of the tariffs on tech capex have been overdone.
Throwing yet another wrench into the markets, there is labor market data to process.
Big tech has dominated the markets, but with tariffs and market uncertainty, what should investors do with the sector now? Ivana Delevska, Spear Invest Founder and CIO, joins Wealth to give some tips on investing in the tech space right now.